A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)-Reference-Cited by-同舟云学术

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

Published:2015-01 Issue:1 Volume:10 Page:143-147
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lilenbaum Rogerio,Samuels Michael,Wang Xiaofei,Kong Feng Ming,Jänne Pasi A.,Masters Gregory,Katragadda Sreedhar,Hodgson Lydia,Bogart Jeffrey,Bradley Jeffrey,Vokes Everett

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference8 articles.

1. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer;Salama;J Clin Oncol,2013

2. Treatment outcomes of different prognostic groups on Cancer and Leukemia Group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared to chemoradiotherapy alone for unresectable stage III non-small cell lung cancer;Stinchcombe;J Thorac Oncol,2009

3. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome?;Raben;J Clin Oncol,2012

4. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial;Ready;J Thorac Oncol,2010

5. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023;Kelly;J Clin Oncol,2008

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapy in the management of lung oligometastases;Cancer/Radiothérapie;2024-02

3. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives;Lung Cancer;2024-01

4. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer;Expert Review of Anticancer Therapy;2023-08-13

5. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-07